{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:11:55Z","timestamp":1785337915893,"version":"3.55.0"},"reference-count":20,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T00:00:00Z","timestamp":1621123200000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019944","name":"Sanofi-Aventis Deutschland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019944","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals, Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2021,3,22]]},"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Atherosclerotic cardiovascular disease is the leading cause of death and disability in the Western world.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To characterise adults with confirmed coronary heart disease (CHD) and primary heterozygous familial or non-familial hypercholesterolaemia or mixed dyslipidaemia who received alirocumab in a real-world setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This open, prospective, multicentre, non-interventional study, conducted in Germany, enroled patients with confirmed CHD who were treated with alirocumab according to its summary of product characteristics. Prescription was at the physician\u2019s discretion and independent of study participation. Patients were followed for 12 weeks after alirocumab initiation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 245 patients (mean age 62.2 years; 34.0% female) were documented at 90 sites. Overall, 47.7% had familial hypercholesterolaemia, 48.9% non-familial hypercholesterolaemia and 43.8% mixed dyslipidaemia; 74.6% had hypertension and 29.2% diabetes mellitus. The most common lipid-lowering therapy in the 12 months preceding alirocumab was a statin, often in combination with ezetimibe (73.5%). Statin contraindications were documented for 46.2% patients and statin intolerance for 63.8%. The mean low-density lipoprotein cholesterol (LDL-C)-level prior to alirocumab was 150.5\u00b151.6\u2009mg\/dL. Alirocumab prescription was in compliance with German national recommendations and\/or European guidelines. The most common starting dose was 75\u2009mg every other week. Overall, 57% patients reached target LDL-C levels (&lt;70\u2009mg\/dL) after 12 weeks of treatment. Alirocumab was generally well tolerated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In a real-world setting in Germany, alirocumab was prescribed for patients with atherosclerotic cardiovascular disease who had high baseline LDL-C levels with or without statin intolerance. Efficacy and safety were consistent with findings observed in the ODYSSEY Phase III programme.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/openhrt-2021-001572","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T13:10:57Z","timestamp":1621257057000},"page":"e001572","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Intensified lipid-lowering treatment with alirocumab in patients with coronary heart disease"],"prefix":"10.1136","volume":"8","author":[{"given":"Daniel","family":"Steffens","sequence":"first","affiliation":[{"name":"Klinik f\u00fcr Kardiologie, Campus Benjamin Franklin, Charit\u00e9 - Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4970-2110","authenticated-orcid":false,"given":"Peter","family":"Bramlage","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Pharmakologie und Pr\u00e4ventive Medizin GmbH, Cloppenburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Sanofi-Aventis Deutschland GmbH, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Dorn","sequence":"additional","affiliation":[{"name":"Sanofi-Aventis Deutschland GmbH, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W Dieter","family":"Paar","sequence":"additional","affiliation":[{"name":"Sanofi-Aventis Deutschland GmbH, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Scheeff","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Kardiologie, Campus Benjamin Franklin, Charit\u00e9 - Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Kasner","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Kardiologie, Campus Benjamin Franklin, Charit\u00e9 - Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Rauch-Kr\u00f6hnert","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Kardiologie, Campus Benjamin Franklin, Charit\u00e9 - Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,5,17]]},"reference":[{"key":"2025081709461231000_8.1.e001572.1","unstructured":"Nichols M , Townsend N , Luengo-Fernandez R . European cardiovascular disease statistics 2012. European heart network, Brussels. European Society of Cardiology, Sophia Antipolis 2012."},{"key":"2025081709461231000_8.1.e001572.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.08.006"},{"key":"2025081709461231000_8.1.e001572.3","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000659"},{"key":"2025081709461231000_8.1.e001572.4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw106"},{"key":"2025081709461231000_8.1.e001572.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.11.037"},{"key":"2025081709461231000_8.1.e001572.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2014.07.028"},{"key":"2025081709461231000_8.1.e001572.7","unstructured":"Sanofi-Aventis . Alirocumab (Praluent) summary of producr characteristics 2020."},{"key":"2025081709461231000_8.1.e001572.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801174"},{"key":"2025081709461231000_8.1.e001572.9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx549"},{"key":"2025081709461231000_8.1.e001572.10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"2025081709461231000_8.1.e001572.11","unstructured":"Sanofi Aventis Deutschland GmbH . Prospektive nicht-interventionelle Studie zur optimierten Behandlung einer therapierefrakt\u00e4ren heterozygot famili\u00e4ren oder nicht-famili\u00e4ren Hypercholesterin\u00e4mie oder gemischter Dyslipid\u00e4mie mit Alirocumab (PRALUENT\u00ae) bei Patienten mit gesicherter koronarer Herzkrankheit - (OPTIMIZE) 2018 Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte. Available: https:\/\/nebenwirkungen.bund.de\/SharedDocs\/awb\/nis-0401-0500\/0443.html [Accessed 11 Aug 2020]."},{"key":"2025081709461231000_8.1.e001572.12","doi-asserted-by":"crossref","unstructured":"Klose G , Laufs U , M\u00e4rz W , et al . Familial hypercholesterolemia. Deutsches Aerzteblatt 2014.doi:10.3238\/arztebl.2014.0523","DOI":"10.3238\/arztebl.2014.0523"},{"key":"2025081709461231000_8.1.e001572.13","first-page":"704","article-title":"Regional differences in the prevalence of cardiovascular disease","volume":"113","author":"Dornquast","year":"2016","journal-title":"Dtsch Arztebl Int"},{"key":"2025081709461231000_8.1.e001572.14","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2014-306463"},{"key":"2025081709461231000_8.1.e001572.15","doi-asserted-by":"publisher","DOI":"10.1007\/s12471-010-0841-y"},{"key":"2025081709461231000_8.1.e001572.16","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1093\/eurheartj\/ehaa034","article-title":"Application of the 2019 ESC\/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study","volume":"41","author":"Allahyari","year":"2020","journal-title":"Eur Heart J"},{"key":"2025081709461231000_8.1.e001572.17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40801-019-00166-7","article-title":"A retrospective observational study to determine baseline characteristics and early prescribing patterns for patients receiving alirocumab in UK clinical practice","volume":"6","author":"Reynolds","year":"2019","journal-title":"Drugs Real World Outcomes"},{"key":"2025081709461231000_8.1.e001572.18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40801-019-0158-0","article-title":"PEARL: a non-interventional study of real-world alirocumab use in German clinical practice","volume":"6","author":"Parhofer","year":"2019","journal-title":"Drugs Real World Outcomes"},{"key":"2025081709461231000_8.1.e001572.19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40256-020-00411-3","article-title":"PCSK9 inhibitors in a German single-center clinical practice: real-world treatment of patients at high cardiovascular risk over 68 weeks","volume":"21","author":"Hollstein","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"key":"2025081709461231000_8.1.e001572.20","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.recesp.2019.03.019","article-title":"Initial real-world experience with PCSK-9 inhibitors in current indications for reimbursement in Spain","volume":"72","author":"Cordero","year":"2019","journal-title":"Rev Esp Cardiol"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2021-001572","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T16:46:20Z","timestamp":1755449180000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2021-001572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,5,17]]},"published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1136\/openhrt-2021-001572"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2021-001572","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}